Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. (13th May 2020)

• Record Type: Journal Article
• Authors: Roseweir, Antonia K; Park, James H; Hoorn, Sanne ten; Powell, Arfon GMT; Aherne, Susan; Roxburgh, Campbell SD; McMillan, Donald C; Horgan, Paul G; Ryan, Elizabeth; Sheahan, Kieran; Vermeulen, Louis; Paul, James; Harkin, Andrea; Graham, Janet; Sansom, Owen; Church, David N; Tomlinson, Ian; Saunders, Mark; Iveson, Tim J; Edwards, Joanne
• Is Part Of: Journal of pathology. Volume 6:Number 4(2020)
• Page Start: 283
• Page End: 296
• Publication Date: 2020-05-13
• Subjects: colorectal cancer -- subtyping -- histopathology -- adjuvant treatment -- recurrence -- precision medicine; Pathology -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.07
• DOI: 10.1002/cjp2.171
• Languages: English
• ISSNs: 2056-4538

Abstract

Abstract: Histological 'phenotypic subtypes' that classify patients into four groups (immune, canonical, latent and stromal) have previously been demonstrated to stratify survival in a stage I–III colorectal cancer (CRC) pilot cohort. However, clinical utility has not yet been validated. Therefore, this study assessed prognostic value of these subtypes in additional patient cohorts along with associations with risk of recurrence and response to chemotherapy. Two independent stage I–III CRC patient cohorts (internal and external cohort) were utilised to investigate phenotypic subtypes. The primary endpoint was disease‐free survival (DFS) and the secondary endpoint was recurrence risk (RR). Stage II–III patients, from the SCOT adjuvant chemotherapy trial, were utilised to further validate prognostic value and for exploratory analysis assessing associations with adjuvant chemotherapy. In an 893‐patient internal cohort, phenotypic subtype independently associated with DFS ( p = 0.025) and this was attenuated in stage III patients ( p = 0.020). Phenotypic subtype also independently associated with RR ( p < 0.001) in these patients. In a 146‐patient external cohort, phenotypic subtype independently stratified patients by DFS ( p = 0.028), validating their prognostic value. In 1343 SCOT trial patients, the effect of treatment type significantly depended on phenotypic subtype ( p interaction = 0.011). Phenotypic subtype independently associated with DFS in stage III patients receiving FOLFOX ( p = 0.028). Furthermore, the immune subtype significantly associated with better response to FOLFOX compared to CAPOX adjuvant chemotherapy in stage III patients ( p = 0.013). In conclusion, histological phenotypic subtypes are an effective prognostic classification in patients with stage III CRC that associates with risk of recurrence and response to FOLFOX adjuvant chemotherapy.